SG11201808479VA - Live, attenuated alphavirus constructs and methods and uses thereof - Google Patents

Live, attenuated alphavirus constructs and methods and uses thereof

Info

Publication number
SG11201808479VA
SG11201808479VA SG11201808479VA SG11201808479VA SG11201808479VA SG 11201808479V A SG11201808479V A SG 11201808479VA SG 11201808479V A SG11201808479V A SG 11201808479VA SG 11201808479V A SG11201808479V A SG 11201808479VA SG 11201808479V A SG11201808479V A SG 11201808479VA
Authority
SG
Singapore
Prior art keywords
live
international
methods
attenuated
constructs
Prior art date
Application number
SG11201808479VA
Other languages
English (en)
Inventor
Jill Livengood
Timothy Powell
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of SG11201808479VA publication Critical patent/SG11201808479VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SG11201808479VA 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof SG11201808479VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662316264P 2016-03-31 2016-03-31
PCT/US2017/024450 WO2017172698A1 (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Publications (1)

Publication Number Publication Date
SG11201808479VA true SG11201808479VA (en) 2018-10-30

Family

ID=58501809

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201808479VA SG11201808479VA (en) 2016-03-31 2017-03-28 Live, attenuated alphavirus constructs and methods and uses thereof

Country Status (17)

Country Link
US (1) US20190106682A1 (es)
EP (1) EP3436062A1 (es)
JP (1) JP2019509750A (es)
KR (1) KR20180135913A (es)
CN (1) CN109195625A (es)
AU (1) AU2017241669A1 (es)
BR (1) BR112018069079A2 (es)
CA (1) CA3019536A1 (es)
CO (1) CO2018010359A2 (es)
CR (1) CR20180457A (es)
DO (1) DOP2018000209A (es)
EC (1) ECSP18081582A (es)
MX (1) MX2018011839A (es)
PE (1) PE20190178A1 (es)
PH (1) PH12018502120A1 (es)
SG (1) SG11201808479VA (es)
WO (1) WO2017172698A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020013236A (es) 2018-06-06 2021-02-22 Massachusetts Inst Technology Acido ribonucleico (arn) circular para traduccion en celulas eucariotas.
CN110213711B (zh) * 2019-04-22 2021-06-18 腾讯科技（深圳）有限公司 一种常驻点的估计方法、装置、设备和介质
CN114561366B (zh) * 2022-03-30 2023-06-20 西南民族大学 一种山羊库布病毒分离株及其应用
CN117925540B (zh) * 2024-03-22 2024-06-18 北京昭衍新药研究中心股份有限公司 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
CN118127077B (zh) * 2024-05-08 2024-07-16 南京农业大学三亚研究院 基于盖塔病毒骨架的嵌合甲病毒制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112095A1 (en) * 2002-07-09 2005-05-26 Tsu-An Hsu Internal ribosome entry sites for recombinant protein expression
KR101913790B1 (ko) * 2008-01-24 2018-12-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도

Also Published As

Publication number Publication date
WO2017172698A1 (en) 2017-10-05
CA3019536A1 (en) 2017-10-05
PE20190178A1 (es) 2019-02-01
EP3436062A1 (en) 2019-02-06
PH12018502120A1 (en) 2019-07-15
CR20180457A (es) 2019-04-09
MX2018011839A (es) 2019-05-23
US20190106682A1 (en) 2019-04-11
KR20180135913A (ko) 2018-12-21
CO2018010359A2 (es) 2018-12-14
BR112018069079A2 (pt) 2019-01-29
ECSP18081582A (es) 2019-02-28
AU2017241669A1 (en) 2018-11-22
JP2019509750A (ja) 2019-04-11
CN109195625A (zh) 2019-01-11
DOP2018000209A (es) 2019-01-31

Similar Documents

Publication Publication Date Title
SG11201808479VA (en) Live, attenuated alphavirus constructs and methods and uses thereof
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201809710RA (en) Genetically engineered cells and methods of making the same
SG11201901550WA (en) Method and apparatus for data processing
SG11201906161VA (en) Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
SG11201803983UA (en) Transformable tagging compositions, methods, and processes incorporating same
SG11201908478SA (en) Sterilisation method
SG11201807660QA (en) Cyclic di-nucleotide compounds and methods of use
SG11201907846VA (en) Therapeutic rna
SG11201807269PA (en) Filamentous fungal biomats, methods of their production and methods of their use
SG11201910096RA (en) Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201808715RA (en) Electro-polarizable compound and capacitor
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201907650RA (en) Personal therapy and exercise monitoring and oversight devices, systems, and related methods
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201909495PA (en) Combination cancer immunotherapy with pentaaza macrocyclic ring complex
SG11201811831SA (en) Compositions and methods for stabilizing flaviviruses with improved formulations
SG11201407417VA (en) Encoding and reconstruction of residual data based on support information
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201901518WA (en) Methods for producing virus for vaccine production
SG11201804888WA (en) Velocity model update with an inversion gradient
SG11201900123TA (en) Compositions and methods for treating frontotemporal dementia
SG11201809993VA (en) Oncolytic viruses comprising esrage and methods of treating cancer
SG11201902988UA (en) Novel hpv16 non hla-restricted t-cell vaccines, compositions and methods of use thereof